Skip to main content

Phase 3 Metabolic & Obesity Deal Benchmarks

Median Upfront
$1.4B
Range: $928M - $1.9B
Total Deal Value
$5.3B
Range: $4.0B - $6.7B
Royalty Rate
19.4% - 30%
Tiered up to 35%
Dev Milestones
$312M
Range: $246M - $384M

Market Analysis

Phase 3 metabolic & obesity licensing deals carry a median total deal value of $5.3B, with upfront payments ranging from $928M to $1.9B. At this stage, deal structures are shifted toward higher upfront allocations, reflecting reduced regulatory risk and near-term commercial potential. The recommended split allocates 27% to upfront and 73% to milestones.

The metabolic & obesity landscape at the phase 3 stage is characterized by extremely high competitive intensity driven by the GLP-1 revolution and massive obesity market opportunity. Development milestones average $312M, regulatory milestones contribute $663M, and commercial milestones reach $2.9B. Oral formulations, dual/triple incretins, and muscle-sparing approaches command unprecedented deal valuations.

Royalty rates for phase 3 metabolic & obesity deals range from 19.4% to 30% at the base tier, with high-tier escalation to 35%. The reduced risk profile at this stage justifies higher fixed royalty commitments.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for phase 3 metabolic & obesity deals?
Phase 3 metabolic & obesity deals average $1.4B in upfront payments, ranging from $928M to $1.9B. The upfront allocation of 27% of total deal value reflects the clinical stage risk profile.
How are phase 3 metabolic & obesity deal milestones structured?
Milestones account for approximately 73% of total deal value. Development milestones ($312M) represent the largest component, followed by commercial milestones ($2.9B) and regulatory milestones ($663M).
What royalty rates are typical for phase 3 metabolic & obesity licensing?
Base royalty rates range from 19.4% to 30%, with tiered escalation to 23.4%-35% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included